The Bcl-w promoter is activated by β-catenin/TCF4 in human colorectal carcinoma cells

Gene

Volumn 432, Issue 1-2, 2009, Pages 112-117

  Lapham, Abigail ^a   Adams, Jemimah E ^a   Paterson, Alex ^a   Lee, Melanie ^a   Brimmell, Matthew ^a   Packham, Graham ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

catenin; Apoptosis; BCL W; BCL2L2; TCF; Transcription

Indexed keywords

BETA CATENIN; PROTEIN BCL W; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TCF 4; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CELL LINE; CELL STRAIN HCT116; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE ACTIVITY; GENE CONTROL; GENE DELETION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; WILD TYPE;

APOPTOSIS REGULATORY PROTEINS; BETA CATENIN; BINDING SITES; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, NEOPLASM; SEQUENCE DELETION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58649124942     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gene.2008.12.002     Document Type: Article

References (35)

1. Bae I.H., et al. Bcl-w promotes gastric cancer cell invasion by inducing matrix metalloproteinase-2 expression via phosphoinositide 3-kinase, Akt, and Sp1. Cancer Res. 66 (2006) 4991-4995
2. Barker N., and Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov. 5 (2006) 997-1014
3. Cartharius K., et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21 (2005) 2933-2942
4. Chipuk J.E., and Green D.R. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 18 (2008) 157-164
5. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 127 (2006) 469-480
6. da Costa L.T., et al. CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling. Oncogene 18 (1999) 5010-5014
7. Danilkovitch-Miagkova A., Miagkov A., Skeel A., Nakaigawa N., Zbar B., and Leonard E.J. Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol. Cell. Biol. 21 (2001) 5857-5868
8. el-Deiry W.S., Kern S.E., Pietenpol J.A., Kinzler K.W., and Vogelstein B. Definition of a consensus binding site for p53. Nat. Genet. 1 (1992) 45-49
9. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 5 (2005) 876-885
10. Friedlander P., Haupt Y., Prives C., and Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16 (1996) 4961-4971
11. Gibson L., et al. Bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13 (1996) 665-675
12. Habens F., et al. Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes. Oncogene 26 (2007) 1910-1919
13. Kim P.J., Plescia J., Clevers H., Fearon E.R., and Altieri D.C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 362 (2003) 205-209
14. Kitamura S., et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer 83 (2000) 668-673
15. Korinek V., et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275 (1997) 1784-1787
16. Lee H.W., Lee S.S., Lee S.J., and Um H.D. Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res. 63 (2003) 1093-1100
17. Lee M., Lapham A., Brimmell M., Wilkinson H., and Packham G. Inhibition of proteasomal degradation of Mcl-1 by cobalt chloride suppresses cobalt chloride-induced apoptosis in HCT116 colorectal cancer cells. Apoptosis (2008)
18. Lin S.Y., et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4262-4266
19. O'Reilly L.A., et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ. 8 (2001) 486-494
20. Pickering B.M., et al. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26 (2007) 1166-1177
21. Print C.G., et al. Apoptosis regulator bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 12424-12431
22. Pritchard D.M., Print C., O, Reilly L., Adams J.M., Potten C.S., and Hickman J.A. Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine. Oncogene 19 (2000) 3955-3959
23. Quandt K., Frech K., Karas H., Wingender E., and Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23 (1995) 4878-4884
24. Rasola A., et al. A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth. Oncogene 26 (2007) 1078-1087
25. Reed J.C. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 3 (2006) 388-398
26. Ross A.J., et al. Testicular degeneration in Bclw-deficient mice. Nat. Genet. 18 (1998) 251-256
27. Sekine S., Shibata T., Sakamoto M., and Hirohashi S. Target disruption of the mutant beta-catenin gene in colon cancer cell line HCT116: preservation of its malignant phenotype. Oncogene 21 (2002) 5906-5911
28. Tishler R.B., Calderwood S.K., Coleman C.N., and Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 53 (1993) 2212-2216
29. Tran N.L., McDonough W.S., Savitch B.A., Sawyer T.F., Winkles J.A., and Berens M.E. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J. Biol. Chem. 280 (2005) 3483-3492
30. van de Wetering M., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111 (2002) 241-250
31. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., and Buchler M.W. Colorectal cancer. Lancet 365 (2005) 153-165
32. Wilson J.W., et al. Bcl-w expression in colorectal adenocarcinoma. Br. J. Cancer 82 (2000) 178-185
33. Yan W., Samson M., Jegou B., and Toppari J. Bcl-w forms complexes with Bax and Bak, and elevated ratios of Bax/Bcl-w and Bak/Bcl-w correspond to spermatogonial and spermatocyte apoptosis in the testis. Mol. Endocrinol. 14 (2000) 682-699
34. Yochum G.S., McWeeney S., Rajaraman V., Cleland R., Peters S., and Goodman R.H. Serial analysis of chromatin occupancy identifies beta-catenin target genes in colorectal carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3324-3329
35. Youle R.J., and Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9 (2008) 47-59